IMMU - Immunomedics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.00
+0.12 (+0.57%)
As of 3:53PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close20.88
Open21.49
Bid21.05 x 900
Ask21.06 x 900
Day's Range20.36 - 21.49
52 Week Range11.55 - 21.49
Volume3658924
Avg. Volume2,425,434
Market Cap4.1B
Beta (3Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateOct 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.10
  • Signal Says Drug Stock Not Done Climbing
    Schaeffer's Investment Research

    Signal Says Drug Stock Not Done Climbing

    The drug stock is ripe for a short squeeze, too

  • GlobeNewswire

    Immunomedics Announces Closing of Public Offering of Common Stock

    The total number of shares of common stock sold was 16,428,572, composed of 14,285,715 shares of common stock initially offered and an additional 2,142,857 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $17.50 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.

  • Did Hedge Funds Drop The Ball On Immunomedics, Inc. (IMMU) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Immunomedics, Inc. (IMMU) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire

    Immunomedics Announces Pricing of Public Offering of Common Stock

    In addition, Immunomedics has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.

  • Immunomedics Resubmits Application for Breast Cancer Drug
    Zacks

    Immunomedics Resubmits Application for Breast Cancer Drug

    Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • GlobeNewswire

    Immunomedics Announces Proposed Public Offering of Common Stock

    In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $37,500,000 of shares of common stock sold in connection with the offering at the public offering price. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.

  • GlobeNewswire

    Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

    MORRIS PLAINS, N.J., Dec. 03, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.

  • Implied Volatility Surging for Immunomedics (IMMU) Stock Options
    Zacks

    Implied Volatility Surging for Immunomedics (IMMU) Stock Options

    Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

  • Benzinga

    The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

    Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a  positive ...

  • GlobeNewswire

    Immunomedics to Present at Upcoming Healthcare Conferences

    MORRIS PLAINS, N.J., Nov. 13, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.

  • Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
    Zacks

    Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

    Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of IMMU earnings conference call or presentation 30-Oct-19 9:00pm GMT

    Q3 2019 Immunomedics Inc Earnings Call

  • Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3
    Zacks

    Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3

    Immunomedics' (IMMU) loss lags estimates in Q3. The company fails to generate any revenues at the same time.

  • GlobeNewswire

    Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA.

  • 3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment
    TipRanks

    3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment

    When it comes to stocks that can shoot up overnight, biotechs are the name of the game. This group’s extreme volatility lies in the fact that a single piece of good news like promising study results can cause share prices to climb to new heights, while the reverse also holds true.As a result, it’s often difficult to determine if names in this industry represent compelling investments. That being said, there are tools available that can help gauge which biotech stocks are poised for substantial long-term growth.Using TipRanks’ Best Stocks to Buy tool, we were able to zero in on 3 biotech stocks that have achieved a “Perfect 10” Smart Score. The metric weighs a variety of factors and combines them into a single numerical score, with 10 being the highest. Not to mention each has earned a ‘Strong Buy’ consensus rating, according to all of the ratings published by analysts in the last three months. Alexion Pharmaceuticals (ALXN)Alexion wants to improve the lives of patients suffering from rare diseases such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), hypophosphatasia (HPP) and other conditions. While best known for its Soliris therapy to treat aHUS, a disease that causes abnormal blood clots to form in small blood vessels in the kidneys, the company has recently expanded its pipeline and has several candidates in development.In its most recent quarter, ALXN highlighted its deals with Eidos, Stealth and Achillion as part of its efforts to diversify its offerings. It also expects to add four new clinical stage assets, including two in Phase 3 development. Bearing this in mind, management raised its total revenue guidance to between $4.86 billion to $4.89 billion. If achieved, this would demonstrate an 18% year-over-year gain at the midpoint of the range.With all of these promising developments, it’s no wonder that nine analysts have published bullish calls in just the last ten days. One of the analysts singing ALXN’s praises is Citigroup’s Mohit Bansal. He argues that the biotech is a growth stock trading like a value stock. He adds that the “strong” revenue guidance and recently expanded pipeline may be of interest to incremental investors. As a result, Bansal reiterated his Buy rating. (To watch Bansal’s track record, click here)The rest of the Street appears to echo the analyst’s sentiment. In just the last three months, ALXN has received 16 Buy ratings and 2 Holds, giving it a ‘Strong Buy’ analyst consensus. Its $155 average price target suggests 48% upside potential. (See Alexion stock analysis on TipRanks) Immunomedics (IMMU)Immunomedics uses antibody-based therapies to develop treatments for cancer, autoimmune and other diseases. With the company recently launching studies back in April and May, buzz surrounding this biotech has been building.The company recently announced the launch of its registrational Phase 3 study for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer. The study of its IMMU-132 drug will feature patients that have experienced failure of at least two but no more than four prior chemotherapy regimens for metastatic disease. IMMU also launched a Phase 2 open label study of its sacituzumab govitecan therapy to treat advanced solid tumors.On top of these trials, the biotech is recruiting for a Phase 2 trial of sacituzumab govitecan for patients with metastatic (Stage IV) urothelial cancer after failure of a platinum-based regimen and/or anti-PD-1/PD-L1 based therapies. While investors will have to wait for the results from the trials, Piper Jaffray analyst Joseph Catanzaro sees significant upside in store for IMMU.“We believe Immunomedics is very well-positioned within triple-negative breast cancer and urothelial bladder cancer,” he commented. Based on all of the above factors, the analyst reiterated his Buy rating and $20 price target. This price target conveys his confidence in IMMU’s ability to surge 23% over the next twelve months. (To watch Catanzaro’s track record, click here)With only Buy ratings assigned in the last three months, the word on the Street is clear: IMMU is a ‘Strong Buy’. Additionally, it boasts 58% upside potential thanks to its $26 average price target. (See Immunomedics stock analysis on TipRanks) Coherus Biosciences (CHRS)By developing biosimilar treatments, Coherus hopes to give patients access to more affordable drugs. A biosimilar drug is a medicine or therapy that is very similar to an already approved biological medicine. While it may seem counterintuitive to develop a drug that resembles something already on the market, they are beneficial in that they provide more treatment options and potentially reduce costs.Following the January 3 launch of its UDENYCA drug to decrease the occurrence of infection in patients receiving anti-cancer drugs, the company has been performing solidly. CHRS saw its UDENYCA net sales reach about $120 million in the first half of 2019. Management stated that this figure was bolstered by strong exit unit market share of 13% at the end of June.All of this led to a 125% increase in net product revenue from the first quarter to the second. With the company developing a therapy similar to Amgen’s Enbrel drug to treat rheumatoid arthritis, some analysts tell investors CHRS is primed for strong long-term growth.Barclays’ Balaji Prasad is one of the analysts maintaining a bullish thesis. While stating that shares experienced some weakness following AMGN’s favorable Enbrel patent ruling against Novartis, he remains very optimistic. He views any share weakness as an opportunity to add a "fundamentally sound company”. This played into his decision to reiterate his Buy rating and $31 price target. (To watch Prasad’s track record, click here)Similarly, other analysts take a bullish approach when it comes to CHRS. It earns a ‘Strong Buy’ Street consensus based on the 6 Buy ratings assigned over the last three months. The biotech stock’s potential twelve-month gain also comes in at 91% according to its $32 average price target. (See Coherus stock analysis on TipRanks)

  • Hedge Funds Don’t Love Immunomedics, Inc. (IMMU) Anymore
    Insider Monkey

    Hedge Funds Don’t Love Immunomedics, Inc. (IMMU) Anymore

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]

  • Benzinga

    Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

    Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. Sacituzumab is in the most advanced stage of clinical development for treating patients with metastatic triple negative breast cancer, or mTNBC. On July 18, 2018, the FDA accepted the BLA for the regulatory review of sacituzumab govitecan as a treatment option for mTNBC in the third-line setting and above, fixing the PDUFA action date at Jan. 18, 2019.

  • GlobeNewswire

    Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019

    Immunomedics, Inc. (IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the third quarter of 2019 and provide a corporate update. The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days.

  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Oct. 11

    Insiders invest in Assured Guaranty, Keurig Dr Pepper, Immunomedics and Advanced Drainage Systems Continue reading...

  • ACCESSWIRE

    SHAREHOLDER REMINDER: Immunomedics, Inc. (IMMU) Sued for Misleading Shareholders; The Law Offices of Timothy L. Miles Encourages Immunomedics Shareholders to Contact the Firm

    HENDERSONVILLE, TN / ACCESSWIRE / October 9, 2019 / The Law Offices of Timothy L. Miles, who has been leading the fight to protect shareholder rights for over 18 years, reminds shareholders that purchasers ...

  • Benzinga

    Notable Insider Buys In The Past Week: Immunomedics, Tenet Healthcare, Ulta Beauty

    Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. An Immunomedics, Inc. (NASDAQ: IMMU) director and an executive each stepped up to the buy window this past week. The company released positive trial data at the European Society for Medical Oncology (ESMO) Annual Congress.

  • Trade Alert: The  Of Immunomedics, Inc. (NASDAQ:IMMU), Bryan Ball, Has Just Spent US$71k Buying Shares
    Simply Wall St.

    Trade Alert: The Of Immunomedics, Inc. (NASDAQ:IMMU), Bryan Ball, Has Just Spent US$71k Buying Shares

    Whilst it may not be a huge deal, we thought it was good to see that Bryan Ball, who is a company insider, recently...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, In. Bragar Eagel & Squire is investigating certain officers and directors of Healthcare Services Group, Inc. following a class action complaint that was filed against Healthcare Services on March 22, 2019.

  • Immunomedics (IMMU) Reports Interim Urothelial Cancer Data
    Zacks

    Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

    Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.